Status:
TERMINATED
Abuse Potential of Buprenorphine/Naloxone
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
Johns Hopkins University
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of ...
Detailed Description
Buprenorphine, a mixed agonist-antagonist opioid (or partial agonist), is a safe and effective treatment for opioid dependence. However, there is concern that buprenorphine may be abused due to its hi...
Eligibility Criteria
Inclusion
- Actively abusing illegal opioids
- Qualifies for opioid substitution treatment (e.g., methadone or buprenorphine), but not in active treatment at the time of study entry
- Meets DSM-IV criteria for opioid dependence
Exclusion
- Significant medical problems (e.g., insulin dependent diabetes mellitus)
- Non-substance use psychiatric disorders (e.g., schizophrenia)
- Seeking substance abuse treatment
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00149539
Start Date
June 1 2004
End Date
January 1 2006
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823